



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Sofituzumab vedotin (solution)

<b>Cat. No.:</b>	HY-P99593A
<b>CAS No.:</b>	1418200-58-4
<b>Target:</b>	Antibody-Drug Conjugates (ADCs)
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker <sup>[1][2]</sup> .									
<b>In Vitro</b>	<p>Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000 ng/mL; 3 or 5 days) inhibits OVCAR-3 and PC3/MUC16Tmlong cells proliferation in a dose-dependent manner<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>OVCAR-3 and PC3/MUC16Tmlong cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1-10000 ng/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>3 days for OVCAR-3 and 5 days for PC3/MUC16Tmlong</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited cell proliferation above 100 ng/mL.</td> </tr> </table>		Cell Line:	OVCAR-3 and PC3/MUC16Tmlong cells	Concentration:	0.1-10000 ng/mL	Incubation Time:	3 days for OVCAR-3 and 5 days for PC3/MUC16Tmlong	Result:	Significantly inhibited cell proliferation above 100 ng/mL.
Cell Line:	OVCAR-3 and PC3/MUC16Tmlong cells									
Concentration:	0.1-10000 ng/mL									
Incubation Time:	3 days for OVCAR-3 and 5 days for PC3/MUC16Tmlong									
Result:	Significantly inhibited cell proliferation above 100 ng/mL.									
<b>In Vivo</b>	<p>Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts<sup>[3]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>2.8 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IV, once weekly for 4 total doses</td> </tr> <tr> <td>Result:</td> <td>Improved survival.</td> </tr> </table>		Animal Model:	Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts <sup>[3]</sup> .	Dosage:	2.8 mg/kg	Administration:	IV, once weekly for 4 total doses	Result:	Improved survival.
Animal Model:	Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts <sup>[3]</sup> .									
Dosage:	2.8 mg/kg									
Administration:	IV, once weekly for 4 total doses									
Result:	Improved survival.									

### REFERENCES

---

[1]. Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. *Cancers (Basel)*. 2020 Aug 9;12(8):2223.

[2]. Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. *Ann Oncol*. 2016 Nov;27(11):2124-2130.

[3]. Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. *Cancer Res*. 2007 May 15;67(10):4924-32.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA